ArticleCureus2025
Radiation Therapy for Maxillary Sinus Epithelioid Hemangioendothelioma: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor arising from endothelial cells, with potential involvement of various anatomical sites. We report the case of a 37-year-old woman presenting with a locally advanced recurrence of maxillary sinus EHE. Due to the tumor's extent and anatomical constraints, complete surgical resection was not feasible. The patient was treated with intensity-modulated radiotherapy (IMRT), achieving a favorable clinical and radiological response. This case highlights the potential of IMRT as an effective therapeutic option for unresectable, locally advanced EHE, with acceptable acute toxicity. Systemic therapy may also be considered in aggressive forms to improve symptom control and progression-free survival (PFS). However, the optimal sequence between systemic treatment and radiotherapy remains unclear when surgery is not an option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.